Distant lymph node metastases caused by esophageal cancer invasion to the lamina propria: a case report by unknown
CASE REPORT Open Access
Distant lymph node metastases caused by
esophageal cancer invasion to the lamina
propria: a case report
Satoshi Tsutsumi1, Hiroshi Saeki1*, Yuichiro Nakashima1, Yu Nakaji1,2, Kensuke Kudou1, Ryosuke Tsutsumi1,
Sho Nishimura1, Shingo Akiyama1, Hirotada Tajiri1, Takafumi Yukaya1, Kimihiro Tanaka1, Ryota Nakanishi1,
Masahiko Sugiyama1, Kippei Ohgaki1, Hideto Sonoda1, Minako Hirahashi2, Eiji Oki1, Masaru Morita3,
Yoshinao Oda2 and Yoshihiko Maehara1
Abstract
Background: Pathological examination after endoscopic submucosal dissection revealed that a 62-year-old male
had esophageal squamous cell carcinoma with lamina propria mucosal invasion and lymphatic permeation.
Case presentation: The patient underwent subtotal esophagectomy and reconstruction as an additional therapy.
At 3 years and 4 months after esophagectomy, enlargement of abdominal para-aortic lymph nodes metastases was
detected by computed tomography scanning. A total of 50.4 Gy of radiation and two cycles of 5-fluorouracil plus
cisplatin were administered. The lymph node metastases were markedly reduced by chemoradiotherapy; however,
at 1 year and 1 month later (4 years and 5 months after esophagectomy), left adrenal gland recurrence was found.
Although resection was performed, the patient died from cancer progression at 5 years and 4 months after
esophagectomy.
Conclusions: This case demonstrates that esophageal squamous cell carcinoma with invasion to the lamina propria
and lymphatic permeation has the potential to cause distant metastases.
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Background
Although lymph node recurrence is common in esopha-
geal cancer, it is rare in tumors restricted to the mucosal
layer. In Japan, superficial esophageal squamous cell car-
cinoma (ESCC) is classified into four subtypes: tumor in
epithelium (T1a-EP); tumor invasion to lamina propria
mucosa (T1a-LPM); tumor invasion to muscularis mucosa
(T1a-MM); and tumor invasion to the upper/middle/lower
third of the submucosal layer (T1b-SM1/2/3) [1]. Among a
case series of 75 surgically resected tumors, none of the
T1a-EP and T1a-LPM cases had lymph node metastasis or
lymphatic permeation, whereas T1a-MM and T1a-SM1,
SM2, SM3 cases had lymph node metastasis (18, 47, 36,
and 62%, respectively) and lymphatic permeation (54, 70,
54, and 75%, respectively) [2]. Other reports indicate that
lymphatic permeation is rare in T1a-LPM esophageal can-
cer, and lymphatic and vascular permeation correlate with
lymph node metastasis and recurrence [3, 4].
Based on the Guidelines for the Diagnosis and
Treatment of Esophageal Cancers 2012 [1], endoscopic
submucosal dissection (ESD) is an absolute indication
for T1a-EP/T1a-LPM permeation without lymph node
or distant metastases. ESD is a relative indication for
T1a-MM/T1b-SM1 permeation without lymph node or
distant metastases, depending on size and location for
complete tumor extraction. For T1a-MM/T1a-SM with
lymphovascular permeation, additional treatment such
as surgery and chemoradiotherapy (CRT) should be
considered because the presence of microscopic lymph
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node metastasis cannot be eliminated, even if lymph
node metastasis is not detected [5].
This report describes a case of ESD followed by an
additional esophagectomy for T1a-LPM ESCC with
lymphatic permeation, in which distant metastasis was
found over 3 years after surgery.
Case presentation
A 62-year-old male underwent upper gastrointestinal en-
doscopy as a screening examination and was diagnosed
with early ESCC. A 0-IIc type Lugol-voiding lesion was
detected in the lower thoracic esophagus. There was no
evidence of submucosal invasion by esophagography, nar-
row band imaging, or endoscopic ultrasonography. Patho-
logical biopsy examination revealed well-differentiated
ESCC. Computed tomography (CT) scanning detected
neither lymph node nor distant organ metastases. As a re-
sult, ESD was performed as the initial therapy (Fig. 1). The
pathological findings demonstrated well-differentiated
ESCC with invasion of the lamina propria and lymphatic
permeation (Fig. 2). No tumor cells were present in the
proximal, distal, and radial margins. As additional therapy,
subtotal esophagectomy and reconstruction were per-
formed with a gastric tube via the posterior mediastinal
route. Pathological examination of the resected specimen
revealed no residual primary lesions and no metastases in
any of the dissected lymph nodes. The patient had an
uneventful postoperative course, with hospital discharge
at 14 days after surgery.
At 3 years and 4 months after esophagectomy, en-
largement of abdominal para-aortic lymph nodes was
detected by follow-up CT scan and subsequently con-
firmed as recurrence of esophageal cancer by positron
emission tomography (PET)-CT scanning (Fig. 3a). Two
cycles of 5-fluorouracil (5-FU; 700 mg/m2 on days 1 to 4)
combined with cisplatin (70 mg/m2 on day 1) and radi-
ation (total 50.4 Gy/28 Fr) were administered, after which,
the abdominal para-aortic lymph node metastases reduced
markedly. At 1 year after chemoradiotherapy (4 years and
5 months after esophagectomy), left adrenal gland recur-
rence was found by PET-CT scan (Fig. 3b). The left ad-
renal gland tumor was resected. Pathological examination
revealed that most of the normal adrenal cells had been
replaced by well-differentiated squamous cell carcinoma
cells with the same degree of differentiation as the primary
lesion. At this time, the abdominal para-aortic lymph node
metastases that had been treated with chemoradiotherapy
were not detected by PET-CT scan; these nodes were
therefore not resected. However, 5 months later (5 years
and 1 month after esophagectomy), distant recurrence in
the liver, right adrenal gland and abdominal lymph nodes,
was recognized by CT scan (Fig. 3c). The patient died
from cancer progression 3 months later (5 years and
4 months after esophagectomy).
Discussion
Lymphatic permeation is rare in T1a-LPM ESCC.
Kodama et al. reported that lymph node metastasis
occurred in 3.3%, lymphatic permeation in 6.5%, and
vascular permeation in 0.4% of T1a-LPM cases [3].
Yamashita et al. reported that 5-year metastasis rates
for EP/LPM, MM, SM1, and SM2 ESCC were 0.4, 8.7,
7.7, and 36.2%, respectively and for mucosal cancer
with and without lymphovascular permeation, 46.7 and
0.7%, respectively [4]. Because the present case was
T1a-LPM ESCC with lymphatic permeation, the risk of
lymph node or distant recurrence was considered to be
low. Therefore, to eliminate the possibility of under-
diagnosis, histopathological examination of the ESD
Fig. 1 Clinical findings. a Endoscopic findings of 0-IIc type Lugol-voiding lesion in the lower thoracic esophagus. b ESD findings. c Resected speci-
men. The black and red lines indicate the cut line and the range of tumor lesion, respectively
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specimen was repeated. Additional cutting of the speci-
men did not reveal any new malignancies, and the diagno-
sis was T1a-LPM ESCC with lymphatic permeation.
Because the para-aortic lymph node metastases were
not resected and were therefore not examined pathologic-
ally, it was difficult to determine whether the adrenal
gland metastasis was from the primary lesion or from
para-aortic lymph node metastases. Of note, pathological
examination of the metastatic adrenal tumor revealed that
most normal adrenal cells had been replaced by well-
differentiated squamous cell carcinoma cells with the
same degree of differentiation as the primary lesion, sug-
gesting that the metastatic adrenal tumor had originated
from the primary lesion.
In cases of lymphatic permeation, the guidelines rec-
ommend that additional therapy such as surgical resec-
tion by esophagectomy or chemoradiotherapy should
be considered. Because surgery enables the dissection
of lymph nodes, it is expected to be a definite cure [6].
Motoyama et al. reported that among 17 patients with
an initial clinical diagnosis of mucosal cancer without
lymph node metastasis in thoracic ESCC, after ESD by
additional esophagectomy with lymphadenectomy, patho-
logical examination revealed that 5 (29%) patients had
submucosal tumor invasion and the involvement of one to
two lymph nodes in the lower mediastinum and abdomen.
Therefore, surgical lymph node dissection is necessary
and an effective treatment for this patient population [7].
However, surgery is invasive and is associated with serious
risks such as postoperative complications and mortality.
Esophagectomy may be challenging to perform in elderly
patients, and those with cardiac or pulmonary complica-
tions. Saeki et al. reported that postoperative complica-
tions were observed in 10 of 34 patients who underwent
additional esophagectomy after ESD. One patient died
from pulmonary complications, but no postoperative re-
currences were detected during the follow-up period [5].
Motoyama et al. reported that 4 of 17 patients (24%) who
underwent esophagectomy developed an anastomotic fis-
tula, but these were healed with conservative therapy, and
surgery was not necessary. Pneumonia occurred in 3 pa-
tients (14%). Recurrent nerve palsy occurred in 4 patients
Fig. 2 Histopathological findings. a Histopathological data reveal well-differentiated squamous cell carcinoma invading the lamina propria (T1a-LPM)
(×20). b Yellow arrows indicate lymphatic permeation of tumor cells (×200)
Fig. 3 Recurrence findings. a Positron emission tomography-computed tomography scan findings of abdominal para-aortic lymph node recurrence at
3 years and 4 months after esophagectomy. b PET-CT scan of left adrenal gland recurrence at 4 years and 5 months after esophagectomy. c CT scan
of liver and right adrenal recurrence at 5 years and 1 month after esophagectomy
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(24%), but it was resolved [7]. These findings suggest that
esophagectomy after ESD provides favorable disease con-
trol for ESCC with pT1a-MM/pSM and/or vessel perme-
ation. Nevertheless, careful consideration should be given
to the indication for an invasive surgical procedure.
Chemoradiotherapy is useful for patients with complica-
tions such as local and distant metastasis, and it plays a
role in ESCC treatment by eliminating some micro-
metastases. Yamamoto et al. reported that the overall sur-
vival rate of patients with clinical stage I ESCC was similar
for chemoradiotherapy versus esophagectomy, despite a
higher local recurrence rate after esophagectomy. Local
carcinoma recurrences were treated by endoscopy in most
patients, with no effect on overall survival [8]. Thus,
chemoradiotherapy appears to be a viable alternative to
esophagectomy in patients with clinical stage I ESCC.
Kawaguchi et al. reported that chemoradiotherapy after
ESD was an effective and safe approach for T1a-MM or
T1b ESCCs. The combination of ESD and chemoradio-
therapy improved the local control rate relative to chemo-
radiotherapy alone [9].
There is accumulating evidence on the efficacy of che-
moradiotherapy for early-stage ESCC. A clinical trial con-
ducted by the Japan Clinical Oncology Group (JCOG9702)
showed that the complete response rate after chemoradio-
therapy with 5-FU plus cisplatin in patients with stage I
ESCC was 87.5%, and the 4-year survival rate was 80.5%
[10]. These results are similar to those reported for esopha-
gectomy in stage I patients [11]. JCOG has initiated a mul-
ticenter phase III trial (JCOG0502) to evaluate the efficacy
and safety of chemoradiotherapy versus esophagectomy for
clinical stage I esophageal cancer. In addition, results from
a phase III trial (JCOG0508) on the efficacy of ESD com-
bined with chemoradiotherapy for clinical stage I esopha-
geal carcinoma are anticipated.
No definitive conclusions can be drawn from the current
case concerning whether esophagectomy or chemoradio-
therapy constitutes optimal treatment after ESD in patients
with pT1a and vessel invasion. However, because this dis-
ease is extremely rare, it would be impractical to attempt
to determine the superiority of additional treatment by
conducting randomized controlled trials. Further findings
from multiple institutes must be reported to enable discus-
sion of the optimal treatment strategy.
Conclusions
ESCC with lamina propria invasion and lymphatic perme-
ation may have the malignancy potential to cause distant
metastasis. For cases with lymphovascular permeation, even
if the tumor depth corresponds to T1a-MM or LPM, it is
important to be aware of the possibility of distant metasta-
sis after additional esophagectomy. Thus, strict follow-up is
required in this patient population.
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